Your session is about to expire
← Back to Search
PBF-1129 + Nivolumab for Lung Cancer
Study Summary
This trial is testing a combination of two immunotherapy drugs to treat NSCLC that has returned or spread. The drugs may help the immune system attack the cancer and prevent tumor cells from growing and spreading.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have brain metastases that have not been treated yet. If you have already been treated for brain metastases and are doing well, you may still be eligible.You have a recent tumor tissue sample stored in a special way, or you can provide unstained slides with tissue samples from a recent tumor biopsy or surgery.Your albumin levels are at least 2.5 mg/dL.Your blood clotting time is not too fast or too slow, unless you are taking medication to control it.You had bad side effects from a previous treatment with a checkpoint inhibitor.If you have a specific gene mutation that can be treated with FDA-approved medications, you must have already tried all the standard treatments for that mutation. For example, if you have an EGFR mutation, you should have already tried osimertinib.Your bilirubin levels in the blood should be within a certain range.You have advanced lung cancer that has come back or spread, and there are no options to cure it.You have a current, ongoing infection with HIV, Hepatitis B, or Hepatitis C.Your platelet count is at least 100,000 per microliter.You have a weakened immune system or are taking certain medications that weaken your immune system.You have a disease that can be measured using specific guidelines.Your heart's electrical activity shows signs of potential problems, such as a very long QT interval or any important abnormalities in your resting ECG.You are able to perform everyday activities without any problem or with a little restriction.You have enough infection-fighting white blood cells in your body.You have a condition where your immune system attacks your own body and have needed strong treatment for it in the past 2 years.You have already tried standard chemotherapy and immunotherapy. You may have had up to 3 previous treatments for your condition.You have severe liver cirrhosis or serious complications from cirrhosis such as hepatic encephalopathy or significant fluid buildup in the abdomen.You agree to give blood samples for additional research.Your kidney function is within a certain range, and your creatinine levels are not too high.Your liver enzymes (AST and ALT) should not be more than 2.5 times the upper limit of normal. If you have liver spread, they should not be more than 5 times the upper limit of normal.If you are a woman who could become pregnant, you must have a negative pregnancy test within a week before starting the treatment.
- Group 1: Treatment (PBF-1129, nivolumab)
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current size of the patient cohort for this clinical trial?
"Affirmative. According to the information available on clinicaltrials.gov, this medical experiment is actively searching for potential candidates. This trial was initially posted in November of 2022 and its parameters were last revised 13th October 2022; 30 patients need to be enrolled from a solitary research site."
Is this research initiative presently searching for participants?
"Affirmative. Data hosted on clinicaltrials.gov verifies that this medical research, which was initially published on November 1st 2022, is still actively recruiting patients. 30 individuals will have to be accepted from a single site in order for the trial to reach completion."
Has the Adenosine A2B Receptor Antagonist PBF-1129 been granted regulatory clearance?
"PBF-1129, an Adenosine A2B Receptor Antagonist, has limited clinical evidence of safety and efficacy; our team therefore rated it a 1 on the scale from 1 to 3."
Share this study with friends
Copy Link
Messenger